Memantine Improves Attentional Processes in Fragile X-Associated Tremor/Ataxia Syndrome: Electrophysiological Evidence from a Randomized Controlled Trial

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yang, Jin Chen ^a,b   Rodriguez, Annette ^a,c   Royston, Ashley ^a   Niu, Yu Qiong ^a,b   Avar, Merve ^a,d   Brill, Ryan ^a,b   Simon, Christa ^a,b   Grigsby, Jim ^e   Hagerman, Randi J ^b,f   Olichney, John M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; MEMANTINE;

AGED; ATAXIA; ATTENTION; COGNITIVE DYSFUNCTION; COMPLICATION; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; EVOKED RESPONSE; EXECUTIVE FUNCTION; FEMALE; FRAGILE X SYNDROME; HUMAN; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHORT TERM MEMORY; TREATMENT OUTCOME; TREMOR;

AGED; ATAXIA; ATTENTION; COGNITIVE DYSFUNCTION; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; EXCITATORY AMINO ACID ANTAGONISTS; EXECUTIVE FUNCTION; FEMALE; FRAGILE X SYNDROME; HUMANS; MALE; MEMANTINE; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TREMOR;

EID: 84959091509     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21719     Document Type: Article

References (58)

1. Seltzer, M. M. et al. Prevalence of CGG Expansions of the FMR1 Gene in a US Population-Based Sample. Am J Med Genet B Neuropsychiatr Genet 159B, 589-597, doi: 10.1002/ajmg.b.32065 (2012).
2. Hagerman, R. & Hagerman, P. Advances in Clinical and Molecular Understanding of the FMR1 Premutation and Fragile x-Associated Tremor/Ataxia Syndrome. Lancet Neurol 12, 786-798 (2013).
3. Hagerman, P. J. & Hagerman, R. J. Fragile X-associated tremor/ataxia syndrome. Ann N Y Acad Sci 1338, 58-70, doi: 10.1111/nyas.12693 (2015).
4. Grigsby, J. et al. Cognitive Profile of Fragile X Premutation Carriers with and without Fragile X-Associated Tremor/Ataxia Syndrome. Neuropsychology 22, 48-60, doi: 10.1037/0894-4105.22.1.48 (2008).
5. Brega, A. G. et al. The Primary Cognitive Deficit among Males with Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) is a Dysexecutive Syndrome. J Clin Exp Neuropsychol 30, 853-869, doi: 10.1080/13803390701819044 (2008).
6. Hunter, J. E. et al. No Evidence for a Difference in Neuropsychological Profile Among Carriers and Noncarriers of the FMR1 Premutation in Adults Under the Age of 50. Am J Hum Genet 83, 692-702, doi: 10.1016/j.ajhg.2008.10.021 (2008).
7. Hunter, J. E., Epstein, M. P., Tinker, S. W., Abramowitz, A. & Sherman, S. L. The FMR1 Premutation and Attention-Deficit Hyperactivity Disorder (ADHD): Evidence for a Complex Inheritance. Behav genet 42, 415-422, doi: 10.1007/s10519-011-9520-z (2012).
8. Farzin, F. et al. Autism Spectrum Disorders and Attention-Deficit/Hyperactivity Disorder in Boys with the Fragile X Premutation. J Dev Behav Pediatr 27, 137-144 (2006).
9. Yang, J.-C. et al. Phenotypes of Hypofrontality in Older Female Fragile X Premutation Carriers. Ann Neurol 74, 275-283 (2013).
10. Cornish, K. M., Hocking, D. R., Moss, S. A. & Kogan, C. S. Selective Executive Markers of At Risk Profiles Associated with the Fragile X Premutation. Neurology 77, 618-622 (2011).
11. Hashimoto, R., Backer, K. C., Tassone, F., Hagerman, R. J. & Rivera, S. M. An FMRI Study of the Prefrontal Activity During the Performance of a Working Memory Task in Premutation Carriers of the Fragile X Mental Retardation 1 Gene with and without Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS). J Psychiatr Res 45, 36-43, doi: 10.1016/j.jpsychires.2010.04.030 (2011).
12. Greco, C. M. et al. Neuropathology of Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS). Brain 129, 243-255, doi: 10.1093/brain/awh683 (2006).
13. Brunberg, J. A. et al. Fragile X Premutation Carriers: Characteristic MR Imaging Findings of Adult Male Patients with Progressive Cerebellar and Cognitive Dysfunction. AJNR Am J Neuroradiol 23, 1757-1766 (2002).
14. Hunsaker, M. R., Kim, K., Willemsen, R. & Berman, R. F. CGG Trinucleotide Repeat Length Modulates Neural Plasticity and Spatiotemporal Processing in a Mouse Model of the Fragile X Premutation. Hippocampus 22, 2260-2275, doi: 10.1002/Hipo.22043 (2012).
15. Cao, Z. et al. Clustered Burst Firing in FMR1 Premutation Hippocampal Neurons: Amelioration with Allopregnanolone. Hum Mol Genet 21, 2923-2935, doi: 10.1093/hmg/dds118 (2012).
16. Liu, J. et al. Signaling Defects in iPSC-Derived Fragile X Premutation Neurons. Hum Mol Genet 21, 3795-3805, doi: 10.1093/hmg/dds207 (2012).
17. Reisberg, B. et al. Memantine in Moderate-to-Severe Alzheimer's Disease. N Engl J Med 348, 1333-1341 (2003).
18. Seritan, A. L. et al. Memantine for Fragile X-Associated Tremor/Ataxia Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Psychiatry 75, 264-271 (2014).
19. Yang, J. C. et al. Memantine Effects on Verbal Memory in Fragile X-associated Tremor/Ataxia Syndrome (FXTAS): a Double-Blind Brain Potential Study. Neuropsychopharmacology 39, 2760-2768, doi: 10.1038/npp.2014.122 (2014).
20. Luck, S. J., Ford, J. M., Sarter, M. & Lustig, C. CNTRICS Final Biomarker Selection: Control of Attention. Schinzophr Bull 38, 53-61 (2012).
21. Leiser, S. C., Dunlop, J., Bowlby, M. R. & Devilbiss, D. M. Aligning Strategies for Using EEG as a Surrogate Biomarker: A Review of Preclinical and Clinical Research. Biochem Pharmacol 81, 1408-1421 (2011).
22. Polich, J. Neuropsychology of P300. (Oxford University Press, 2012).
23. Herrmann, C. S. & Knight, R. T. Mechanisms of Human Attention: Event Related Potentials and Oscillations. Neurosci Biobehav Rev 25, 465-476 (2001).
24. Yang, J.-C. et al. Neural Substrates of Executive Dysfunction in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): A Brain Potential Study. Cereb Cortex 23, 2657-2666 (2013).
25. Tikhonravov, D. et al. Dose-Related Effects on Memantine on a Mismatch Negativity-Like Response in Anesthetized Rats. Neuroscience 167, 1175-1182 (2010).
26. Connolly, P. M. et al. The Effects of Ketamine Vary Among Inbred Mouse Strains and Mimic Schizophrenia for the P80, but Not P20 or N40 Auditory ERP Components. Neurochem 29, 1179-1188 (2004).
27. Siegel, S. J. et al. Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice. Neuropsychopharmacology 28, 675-682, doi: 10.1038/sj.npp.1300087 (2003).
28. Ehlers, C. L., Kaneko, W. M., Chaplin, W. & Chaplin, R. I. Effects of Dizocilpine (MK-801) and Ethanol on the EEG and Event-Related Potentials (ERPS) in Rats. Neuropharmacology 31, 369-378 (1992).
29. Ehrlichman, R. S. et al. N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience 158, 705-712, doi: 10.1016/j.neuroscience.2008.10.031 (2009).
30. Korostenskaja, M., Nikulin, V. V., Kicic, D., Nikulina, A. V. & Kahkonen, S. Effects of NMDA Receptor Antagonist on Mismatch Negativity. Brain Res Bull 72, 275-283 (2007).
31. Umbricht, D. et al. Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans. Brain Res 1019, 189-200, doi: 10.1016/j.brainres.2004.05.097 (2004).
32. Umbricht, D., Koller, R., Vollenweider, F. X. & Schieder, L. Mismatch Negativity Predicts Psychotic Experiences Induced by NMDA Receptor Antagonist in Healthy Volunteers. Biol Psychiatry 51, 400-406 (2002).
33. McFall, R. M. & Treat, T. A. Quantifying the information value of clinical assessments with signal detection theory. Annu Rev Psychol 50, 215-241 (1999).
34. Thal, L. J. et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 20, 6-15, doi: 10.1097/01.wad.0000191420.61260.a8 (2006).
35. Gazzaniga, M. S., Ivry, R. B. & Mangun, G. R. Cognitive Neuroscience: the biology of the mind. 3 edn, (W.W. Norton, 2008).
36. Crowley, K. E. & Colrain, I. M. A Review of the Evidence for P2 being an Independent Component Process: Age, Sleep, and Modality. Clin Neurophysiol 115, 732-744 (2004).
37. Melara, R. D., Tong, Y. & Rao, A. Control of Working Memory: Effects of Attention Training on Target Recognition and Distractor Salience in an Auditory Selection Task. Brain Res 68-67 (2012).
38. Verleger, R., Heide, W., Butt, C. & Kompf, D. Reduction of P3b in patients with temporo-parietal lesions. Brain Res Cogn Brain Res 2, 103-116 (1994).
39. Amenedo, E. & Diaz, F. Aging-related changes in processing of non-target and target stimuli during an auditory oddball task. Biol Psychol 48, 235-267 (1998).
40. Melara, R. D., Chen, S. & Wang, H. Inhibiting change: effects of memory on auditory selective attention. Brain Res Cogn Brain Res 25, 431-442, doi: 10.1016/j.cogbrainres.2005.07.002 (2005).
41. Melara, R. D., Rao, A. & Tong, Y. The Duality of Selection: Excitatory and Inhibitory Processes in Auditory Selective Attention. J Exp Psychol Hum Percept Perform 28, 279-306 (2002).
42. McCabe, D. P., Roediger, H. L., McDaniel, M. A., Balota, D. A. & Hambrick, D. Z. The Relationship Between Working Memory Capacity and Executive Functioning: Evidence for a Common Executive Attention Construct. Neuropsychology 24, 222-243, doi: 10.1037/A0017619 (2010).
43. Miyake, A. et al. The unity and diversity of executive functions and their contributions to complex "frontal lobe" tasks: A latent variable analysis. Cognitive Psychol 41, 49-100, doi: 10.1006/cogp.1999.0734 (2000).
44. Polich, J. EEG and ERP assessment of normal aging. Electroencephalogr Clin Neurophysiol 104, 244-256 (1997).
45. Ponton, C. W., Eggermont, J. J., Kwong, B. & Don, M. Maturation of human central auditory system activity: evidence from multi-channel evoked potentials. Clin Neurophysiol 111, 220-236 (2000).
46. Knight, R. T., Scabini, D., Woods, D. L. & Clayworth, C. The effects of lesions of superior temporal gyrus and inferior parietal lobe on temporal and vertex components of the human AEP. Electroencephalogr Clin Neurophysiol 70, 499-509 (1988).
47. Wang, J. Y., Hagerman, R. J. & Rivera, S. M. A multimodal imaging analysis of subcortical gray matter in fragile X premutation carriers. Mov disord 28, 1278-1284 (2013).
48. Moore, C. J. et al. The effect of pre-mutation of X chromosome CGG trinucleotide repeats on brain anatomy. Brain 127, 2672-2681 (2004).
49. Broberg, B. V. et al. Assessment of Auditory Sensory Processing in a Neurodevelopmental Animal Model of Schizophrenia-Gating of Auditory-Evoked Potentials and Prepulse Inhibition. Behav Brain Res 213, 142-147 (2010).
50. de Bruin, N. M., Ellenbroek, B. A., Cools, A. R., Coenen, A. M. & van Luijtelaar, E. L. Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology (Berl) 142, 9-17 (1999).
51. Bickel, S., Lipp, H.-P. & Umbricht, D. Early Auditory Sensory Processing Deficits in Mouse Mutants with Reduced NMDA Receptor Function. Neuropharmacology 33, 1680-1690 (2008).
52. Ortigas, M. C. et al. Improving Fragile X-Associated Tremor/Ataxia Syndrome Symptoms with Memantine and Venlafaxine. J Clin Psychopharmacol 30, 642-644, doi: 10.1097/JCP.0b013e3181f1d10a (2010).
53. Seeman, P., Caruso, C. & Lasaga, M. Memantine agonist action at dopamine D2High receptors. Synapse 62, 149-53, (2008).
54. Niu, Y. Q. et al. Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS): revisited. Parkinsonism Relat Disord 20, 456-459, doi: 10.1016/j.parkreldis.2014.01.006 (2014).
55. Kähkönen, S. et al. Dopamine modulates involuntary attention shifting and reorienting: an electromagnetic study. Clin Neurophysiol 113, 1894-1902 (2002).
56. Sani, G. et al. The Role of Memantine in the Treatment of Psychiatric Disorders Other Than the Dementias: a review of current preclinical and clinical evidence. CNS Drugs 26, 663-690, doi: 10.2165/11634390-000000000-00000 (2012).
57. Serra, G. et al. Memantine: New prospective in bipolar disorder treatment. World J Psychiatry 4, 80-90, doi: 10.5498/wjp.v4.i4.80 (2014).
58. Olichney, J. M. et al. Abnormal N400 word repetition effects in fragile X-associated tremor/ataxia syndrome. Brain 133, 1438-1450, doi: 10.1093/brain/awq077 (2010).